Studies also show that incretin-based therapies like Wegovy and Mounjaro are much less effective ... In 2023, Embark Biotech was acquired by Novo Nordisk to develop next generation therapeutics for ...

US Food and Drug Administration (FDA) regulations allow human drug compounding — in which licensed pharmacists or physicians ...

A roundup of top health news highlights Novo Nordisk's $16.5 billion deal scrutiny, Amgen's weight-loss drug controversy, ...

Amgen stock rebounded Wednesday, shaking off "overdone" fears that its monthly weight-loss shot, MariTide, causes excessive bone mineral density loss.Please watch the video at Investors.com - How Novo ...

In the case of popular medications like Ozempic and Wegovy, the drug manufacturer Novo Nordisk told Global News the company has mitigation plans to minimize any disruption.

Denmark is at the forefront of integrating artificial intelligence within structured regulation, recently launching a new AI ...

European Union seeks input from rival pharmaceutical firms on Novo Holdings' $16.5 billion acquisition of Catalent.

Scientists at the University of Copenhagen have discovered a new weight loss drug target that reduces appetite, increases energy expenditure, and improves insulin sensitivity without causing nausea or ...

Hims & Hers (HIMS) has launched an online GLP-1 supply tracker where people can share information about where the popular ...

Hims & Hers is launching a tracker of GLP-1 shortages to push back against the FDA's recent moves to end compounding copycats ...

Novo Holdings is the controlling shareholder of Danish drugmaker Novo Nordisk, whose profits from blockbuster weight-loss ...